JP2017501695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501695A5 JP2017501695A5 JP2016537434A JP2016537434A JP2017501695A5 JP 2017501695 A5 JP2017501695 A5 JP 2017501695A5 JP 2016537434 A JP2016537434 A JP 2016537434A JP 2016537434 A JP2016537434 A JP 2016537434A JP 2017501695 A5 JP2017501695 A5 JP 2017501695A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- adenovirus according
- adenovirus
- transgene
- cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 14
- 108700019146 Transgenes Proteins 0.000 claims 8
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 108091008035 T cell costimulatory receptors Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322851.5A GB201322851D0 (en) | 2013-12-23 | 2013-12-23 | Method |
| GB1322851.5 | 2013-12-23 | ||
| PCT/EP2014/072919 WO2015059303A1 (en) | 2013-10-25 | 2014-10-24 | Oncolytic adenoviruses armed with heterologous genes |
| EPPCT/EP2014/072919 | 2014-10-24 | ||
| PCT/EP2014/079162 WO2015097220A1 (en) | 2013-12-23 | 2014-12-23 | A method of making adenovirus and corresponding plasmids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020197533A Division JP7104994B2 (ja) | 2013-12-23 | 2020-11-27 | アデノウイルスおよび対応するプラスミドの作製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501695A JP2017501695A (ja) | 2017-01-19 |
| JP2017501695A5 true JP2017501695A5 (enExample) | 2018-02-08 |
| JP6804133B2 JP6804133B2 (ja) | 2020-12-23 |
Family
ID=50114629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537434A Active JP6804133B2 (ja) | 2013-12-23 | 2014-12-23 | アデノウイルスおよび対応するプラスミドの作製方法 |
| JP2020197533A Active JP7104994B2 (ja) | 2013-12-23 | 2020-11-27 | アデノウイルスおよび対応するプラスミドの作製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020197533A Active JP7104994B2 (ja) | 2013-12-23 | 2020-11-27 | アデノウイルスおよび対応するプラスミドの作製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10472648B2 (enExample) |
| JP (2) | JP6804133B2 (enExample) |
| KR (1) | KR20160102024A (enExample) |
| CN (1) | CN106062199B (enExample) |
| AU (1) | AU2014372562B2 (enExample) |
| CA (1) | CA2934015A1 (enExample) |
| GB (1) | GB201322851D0 (enExample) |
| IL (1) | IL246235B (enExample) |
| SG (1) | SG11201604801WA (enExample) |
| WO (1) | WO2015097220A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3021859T3 (pl) | 2013-10-25 | 2018-06-29 | Psioxus Therapeutics Limited | Adenowirusy onkolityczne wyposażone w geny heterolityczne |
| PT3288573T (pt) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Adenovírus oncolítico que codifica uma proteína b7 |
| WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL264902B2 (en) | 2016-08-29 | 2023-11-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| US20200017862A1 (en) * | 2017-03-07 | 2020-01-16 | University Of North Carolina Charlotte | Systems and methods for single-strand break signaling and repair in a cell-free system |
| CN120796389A (zh) * | 2017-05-26 | 2025-10-17 | 埃皮森特Rx股份有限公司 | 携带转基因的重组腺病毒 |
| LT3630143T (lt) * | 2017-06-01 | 2023-09-25 | Akamis Bio Limited | Onkolitinis virusas ir būdas |
| US11268108B2 (en) * | 2017-10-16 | 2022-03-08 | Glaxosmithkline Biologicals Sa | Replication competent adenoviral vectors |
| CN108424932B (zh) * | 2018-03-13 | 2021-01-05 | 北京多赢时代转化医学研究院 | 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用 |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN113186151A (zh) * | 2021-03-03 | 2021-07-30 | 郑州大学 | 一种提高腺病毒产毒能力的单克隆细胞、细胞库及制备方法 |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
| FR2799472B1 (fr) * | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| WO2004087930A1 (en) | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
| CN1221666C (zh) * | 2003-09-02 | 2005-10-05 | 广东省人民医院 | 腺病毒穿梭质粒及其构建方法 |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| KR101169109B1 (ko) | 2004-05-26 | 2012-07-26 | 싸이오서스 테라퓨틱스 엘티디. | 암 치료에 사용하기 위한 키메릭 아데노바이러스 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| BRPI0615400A2 (pt) * | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| CN103237889B (zh) | 2010-08-16 | 2017-04-05 | 萨克生物研究学院 | 腺病毒组装方法 |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| JP2016512199A (ja) | 2013-03-05 | 2016-04-25 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 腫瘍溶解性ウイルス |
| KR20160137946A (ko) | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
| PT3288573T (pt) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Adenovírus oncolítico que codifica uma proteína b7 |
-
2013
- 2013-12-23 GB GBGB1322851.5A patent/GB201322851D0/en not_active Ceased
-
2014
- 2014-12-23 CA CA2934015A patent/CA2934015A1/en not_active Abandoned
- 2014-12-23 SG SG11201604801WA patent/SG11201604801WA/en unknown
- 2014-12-23 CN CN201480074534.7A patent/CN106062199B/zh active Active
- 2014-12-23 JP JP2016537434A patent/JP6804133B2/ja active Active
- 2014-12-23 WO PCT/EP2014/079162 patent/WO2015097220A1/en not_active Ceased
- 2014-12-23 US US15/107,451 patent/US10472648B2/en active Active
- 2014-12-23 KR KR1020167019706A patent/KR20160102024A/ko not_active Withdrawn
- 2014-12-23 AU AU2014372562A patent/AU2014372562B2/en active Active
-
2016
- 2016-06-15 IL IL246235A patent/IL246235B/en active IP Right Grant
-
2020
- 2020-11-27 JP JP2020197533A patent/JP7104994B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501695A5 (enExample) | ||
| JP2018139586A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2017122120A5 (enExample) | ||
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| JP2015506704A5 (enExample) | ||
| JP2016514956A5 (enExample) | ||
| JP2019523008A5 (enExample) | ||
| JP2015533841A5 (enExample) | ||
| RU2019107976A (ru) | Композиция вакцины | |
| WO2018073393A3 (en) | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy | |
| FI3294325T3 (fi) | Car-muokattujen t-solujen vaikutuksen parantaminen nukleeinihapporokotuksella | |
| JP2014503206A5 (enExample) | ||
| EP4286407A3 (en) | Anti-mutated kras t cell receptors | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| JP2016527891A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| JP2014524445A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| Maetzig et al. | All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase |